Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc.
Type	Public
Traded as	Nasdaq: SPPI ;
Industry	Pharmaceuticals
Headquarters	Boston, MA, U.S.
Key people	Tom Riga CEO
Revenue	US$109.33 million (2018)
Owner	Assertio Holdings; (2023–present);
Number of employees	164 (December 31, 2021)
Website	sppirx.com

Last updated December 19, 2023

Spectrum Pharmaceuticals is an American biopharmaceutical company located in Boston, MA. It develops and markets drugs for treatments in hematology and oncology.

Drugs

In January 2019, Spectrum Pharmaceuticals sold its entire portfolio of hematology and oncology related products to Acrotech Biopharma USA, Inc., a New Jersey-based subsidiary of India's Aurobindo Pharma Ltd. The seven drugs had a combined sales of $76.4 million in the first three quarters of 2018.

The products sold were Fusilev (levoleucovorin), Folotyn (pralatexate injection), Zevalin (ibritumomab tiuxetan), Marqibo (vincristine sulfate LIPOSOME injection), Beleodaq (belinostat) for injection, Evomela (melphalan) for injection, and Khapzory (levoleucovorin).

The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets.

In development

As of 2023, Spectrum has one FDA approved drug (ROLVEDON™ (eflapegrastim) is also formerly known as Rolontis) and one drug in advanced development (Poziotinib).

Key Events for Rolvedon

On September 9, 2022, FDA approved ROLVEDON™ (formerly known as Rolontis)(eflapegrastim-xnst) injection indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Development timeline for Rolvedon:

Sep 9, 2022 Spectrum announced FDA Approval of Rolvedon (eflapegrastim-xnst) Injection to Decrease the Incidence of Chemotherapy-Induced Neutropenia

April 11, 2022 FDA announced acceptance of Spectrum's re-submission of its Rolontis Biologics License Application (BLA)to FDA.

Aug 6, 2021 Spectrum received a Complete Response Letter (CRL) from FDA for Rolontis (eflapegrastim). FDA cited to manufacturing deficiencies that required the manufacturing facilities to be re-inspected by FDA.

Oct. 24, 2019 Spectrum re-submitted an updated version of its Biologics License Application (BLA)for ROLONTIS (eflapegrastim) to FDA based on 643 early-stage breast cancer patients. This BLA version included additional information in the Chemistry, Manufacturing and Controls (CMC) section.

Mar 18, 2019 After receiving FDA's request for additional (CMC) chemistry-manufacturing-control related information for Rolontis (eflapegrastim), Spectrum voluntarily withdrew its 2018 Biologics License Application (BLA) from FDA as more than 60 days time would have beenneeded to provide the additional CMC-related information FDA required before March 29, 2019, the end date of FDA's initial 60-day review period.

Dec 27, 2018 Spectrum announced its submission of the Biologics License Application to the FDA for Rolontis (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia based on 643 early-stage breast cancer patients.

Key Research and Development Events for Poziotinib

Poziotinib is a tyrosine kinase inhibitor in development for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations.

Nov 28, 2022 Spectrum announced the lay off 75% of R&D staff after FDA New Drug Application (NDA) rejection. Spectrum also announced plans to discontinue development of poziotinib, and to explore “strategic alternatives” for the Poziotinib program.

Nov 25, 2022 Spectrum received a Complete Response Letter from FDA for Poziotinib.

Sep 22, 2022 Spectrum provided an update on Poziotinib following the FDA Oncologic Drugs Advisory Committee (ODAC) Meeting regarding Spectrum's New Drug Application (NDA).

The ODAC voted 9–4 against a Poziotinib approval as the advisers judged the drug's risks outweighed its benefits.

Feb 11, 2022 Spectrum announced FDA acceptance of the New Drug Application (NDA) submitted for Poziotinib

Dec 6, 2021 Spectrum submitted the New Drug Application (NDA) for Poziotinib.

Mar 11, 2021 FDA Grants Fast Track Designation (FTD) to Spectrum for Poziotinib.

Dec 19, 2018 Spectrum announced that based on a subset of data from MD Anderson's ongoing Phase 2 study, FDA did not grant Breakthrough Therapy Designation (BTD) to Poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations.

Spectrum's BTD application included data from 30 patients from MD Anderson's Phase 2 study who had failed platinum-based chemotherapy.

Spectrum reported that the MDAnderson data demonstrated a confirmed objective response rate of 40% and median duration of response of 6.6 months.

Spectrum stated the safety profile in this subset was consistent with historical data published on poziotinib and other tyrosine kinase inhibitors. The historical objective response rates for mutation specific NSCLC patients range between 0% and 8% with tyrosine kinase inhibitors and for non-mutation specific NSCLC patients range between 0.8% and 22.9% with other treatments.

2018 Spectrum submits Poziotinib application for Breakthrough Therapy Designation (BTD) to FDA based on data reported on patients treated by John Heymach, MD and medical staff at the MD Anderson Cancer Center.

Sep 24, 2018 Spectrum Announced the release of updated Poziotinib data From MD Anderson's Phase 2 Study in Non-Small Cell Lung Cancer Patients.

May 3, 2018 Patent Licensing Agreement announced by and between The University of Texas MD Anderson Cancer Center (MDACC) and Spectrum Pharmaceuticals to cover discoveries by John Heymach, M.D., Ph.D., professor and chair of Thoracic/Head and Neck Medical Oncology, and Heymach's research staff at MDACC in the future.

The filed patents, if granted, are expected to extend the intellectual property protection to 2037.

Oct 27, 2017 Spectrum highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) from research results reported by Dr. John Heymach and The University of Texas MD Anderson Cancer Center.

At the 18th IASLC World Conference on Lung Cancer in Japan, Spectrum presented data reported by Dr. Heymach and the MD Anderson Cancer Center research team illustrating that Poziotinib demonstrated evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with interim data showing an Objective Response Rate of 73%.

Evidence of central nervous system (CNS) activity in a patient with CNS metastasis and another with leptomeningeal disease (LMD).

March 17, 2017 First Poziotinib clinical trial patient enrolled by Dr. John Heymach of MD Anderson Cancer Center into the Investigator Study Protocol 2016–0783.

Feb. 23, 2017 Dr. John Heymach of M.D. Anderson Cancer Center initiated the Investigator IND as the Study Sponsor to of the clinical research, Protocol 2016–0783, “A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors” in collaboration with Spectrum and National Cancer Institute (NCI).

Related Research Articles

Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva.

<span class="mw-page-title-main">Erlotinib</span> EGFR inhibitor for treatment of non-small-cell lung cancer

Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. It is taken by mouth.

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.

<span class="mw-page-title-main">Afatinib</span> Chemical compound

Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient.

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

<span class="mw-page-title-main">Icotinib</span> Chemical compound

Icotinib is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.

<span class="mw-page-title-main">Binimetinib</span> Chemical compound

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma.

Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

<span class="mw-page-title-main">Osimertinib</span> Chemical compound, used as a medication to treat lung cancer

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

Olmutinib (INN) is an investigational anti-cancer drug. It acts by covalently bonding to a cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR).

Eflapegrastim, sold under the brand name Rolvedon among others, is a long-acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals. Eflapegrastim is a leukocyte growth factor. It is used to reduce the risk of febrile neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer agents.

Halozyme Therapeutics is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.

<span class="mw-page-title-main">Selpercatinib</span> Chemical compound

Selpercatinib, sold under the brand name Retevmo among others, is a medication for the treatment of cancers in people whose tumors have an alteration in a specific gene. It is taken by mouth.

<span class="mw-page-title-main">Mobocertinib</span> Small molecule tyrosine kinase inhibitor

Mobocertinib, sold under the brand name Exkivity, is used for the treatment of non-small cell lung cancer.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

References

↑ "Spectrum Pharma Skyrockets on Acquisition by Assertio - TipRanks.com". TipRanks Financial. Retrieved 2023-04-26.
↑ "Assertio picks up Spectrum and its approved drug Rolvedon in $248M-plus deal".
↑ "Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction". Assertio Holdings. Retrieved 2023-08-11.

External links

Official website

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Spectrum Pharma Skyrockets on Acquisition by Assertio - TipRanks.com". TipRanks Financial. Retrieved 2023-04-26.

[2] "Assertio picks up Spectrum and its approved drug Rolvedon in $248M-plus deal".

[3] "Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction". Assertio Holdings. Retrieved 2023-08-11.

[1]

[2]

[3]